Compugen LTD: what the price is pricing in
The price implies cash-flow growth of -20.7% a year; our model expects 13.0%. That gap is wide enough for a long position this quarter. Switch lens below to see the same question asked of earnings, growth, sales and book value.
No published rating for Compugen LTD: held for review: our cash-flow value ($7.89) is 3.92x the share price ($2.01) and 3.03x the median of our other models ($2.60); the other models don't support a gap this wide. The readings below run our models backwards for research and show how trading the gap would have done; they are not a valuation or a rating. The valuation page shows the models and their status.
What growth in cash flow is the price paying for?
The price implies cash-flow growth of -20.7% a year; our model expects 13.0%.
Market more pessimistic than our model: long this quarter
Over time
Skill or luck?
In plain English: With only 2 quarters of positions, Compugen LTD's own record is too short to tell skill from luck. The results across all companies on the priced-in page are the better guide.
| Positions | Quarters | Beat the S&P 500 | Average vs S&P 500, a quarter | Typical (median), a quarter | A year | Confidence (t) | Evidence |
|---|---|---|---|---|---|---|---|
| Longs | 2 | 50.0% | −2.9% | −2.9% | −13.7% | — | Too few quarters |
| Shorts | 0 | — | — | — | — | — | — |
| All positions | 2 | 50.0% | −2.9% | −2.9% | −13.7% | — | Too few quarters |
Every quarter (3)
| From | Price paid | Growth the price implies | Growth our model assumes | Position | CGEN | S&P 500 |
|---|---|---|---|---|---|---|
| September 30, 2026 (open) | $2.38 | -20.7% | 13.0% | Long | −16.8% | −0.8% |
| June 30, 2026 | $2.14 | -25.9% | 13.0% | Long | +11.2% | +2.4% |
| March 31, 2026 | $2.13 | -26.1% | 13.0% | Long | +0.5% | +15.1% |
What growth in earnings is the price paying for?
The price implies earnings growth of -30.0% a year; our model expects 13.0%.
Market more pessimistic than our model: long this quarter
Over time
Skill or luck?
In plain English: With only 2 quarters of positions, Compugen LTD's own record is too short to tell skill from luck. The results across all companies on the priced-in page are the better guide.
| Positions | Quarters | Beat the S&P 500 | Average vs S&P 500, a quarter | Typical (median), a quarter | A year | Confidence (t) | Evidence |
|---|---|---|---|---|---|---|---|
| Longs | 2 | 50.0% | −2.9% | −2.9% | −13.7% | — | Too few quarters |
| Shorts | 0 | — | — | — | — | — | — |
| All positions | 2 | 50.0% | −2.9% | −2.9% | −13.7% | — | Too few quarters |
Every quarter (3)
| From | Price paid | Growth the P/E implies | Growth our model assumes | Position | CGEN | S&P 500 |
|---|---|---|---|---|---|---|
| September 30, 2026 (open) | $2.38 | -30.0%* | 13.0% | Long | −16.8% | −0.8% |
| June 30, 2026 | $2.14 | -30.0%* | 13.0% | Long | +11.2% | +2.4% |
| March 31, 2026 | $2.13 | -30.0%* | 13.0% | Long | +0.5% | +15.1% |
What profit margin is the price paying for?
The price implies an owner-earnings margin of 3.9%; the company has kept 27.1%.
Market more pessimistic than our model: long this quarter
Over time
$10,000 trading the gap vs the S&P 500
Skill or luck?
In plain English: Across 20 quarters with a position, this lens beat the S&P 500 in 12, by +7.7% a quarter on average. That is suggestive but could still be chance. One company is a small sample: the results across all companies are the better guide.
| Positions | Quarters | Beat the S&P 500 | Average vs S&P 500, a quarter | Typical (median), a quarter | A year | Confidence (t) | Evidence |
|---|---|---|---|---|---|---|---|
| Longs | 2 | 50.0% | −2.9% | −2.9% | −13.7% | — | Too few quarters |
| Shorts | 18 | 61.1% | +8.9% | +9.0% | +30.1% | 1.71 | Some evidence |
| All positions | 20 | 60.0% | +7.7% | +7.7% | +24.9% | 1.61 | Some evidence |
Every quarter (21)
| From | Price paid | Margin the price implies | Margin delivered | Position | CGEN | S&P 500 |
|---|---|---|---|---|---|---|
| September 30, 2026 (open) | $2.38 | 3.9% | 27.1% | Long | −16.8% | −0.8% |
| June 30, 2026 | $2.14 | 2.9% | 27.1% | Long | +11.2% | +2.4% |
| March 31, 2026 | $2.13 | 2.8% | 27.1% | Long | +0.5% | +15.1% |
| September 30, 2025 | $1.47 | 6.0% | -46.6% | Short | +4.1% | +2.7% |
| June 30, 2025 | $1.78 | 9.3% | -46.6% | Short | −17.4% | +8.1% |
| March 31, 2025 | $1.46 | 5.9% | -46.6% | Short | +21.9% | +10.8% |
| September 30, 2024 | $1.81 | 11.6% | -225.3% | Short | −15.5% | +2.5% |
| June 30, 2024 | $1.68 | 10.5% | -225.3% | Short | +7.7% | +5.8% |
| March 31, 2024 | $2.58 | 18.1% | -225.3% | Short | −34.9% | +4.4% |
| June 30, 2023 | $1.14 | 4.5% | -628.6% | Short | −18.4% | −3.2% |
| June 30, 2022 | $1.85 | 20.9% | -354.8% | Short | −64.3% | −4.9% |
| March 31, 2022 | $3.22 | 83.0% | -354.8% | Short | −42.5% | −16.1% |
| September 30, 2019 | $4.23 | 23.4% | -288.3% | Short | +40.9% | +9.0% |
| June 30, 2019 | $3.84 | 20.7% | -288.3% | Short | +10.2% | +1.8% |
| March 31, 2019 | $4.14 | 22.8% | -288.3% | Short | −7.3% | +4.2% |
| September 30, 2016 | $6.30 | 82.7% | -236.1% | Short | −19.1% | +4.0% |
| June 30, 2016 | $6.48 | 85.9% | -236.1% | Short | −2.8% | +3.8% |
| March 31, 2016 | $5.58 | 70.1% | -236.1% | Short | +16.1% | +2.5% |
| September 30, 2015 | $5.17 | 46.4% | -255.6% | Short | +23.6% | +7.0% |
| June 30, 2015 | $6.94 | 68.8% | -255.6% | Short | −25.5% | −6.4% |
| March 31, 2015 | $7.05 | 70.2% | -255.6% | Short | −1.6% | +0.2% |
What return on equity is the price paying for?
The price implies a return on equity of 15.5%; the company earned 44.8%.
Market more pessimistic than our model: long this quarter
Over time
$10,000 trading the gap vs the S&P 500
Skill or luck?
In plain English: Across 29 quarters with a position, this lens beat the S&P 500 in 18, by +3.1% a quarter on average. That could easily be chance. One company is a small sample: the results across all companies are the better guide.
| Positions | Quarters | Beat the S&P 500 | Average vs S&P 500, a quarter | Typical (median), a quarter | A year | Confidence (t) | Evidence |
|---|---|---|---|---|---|---|---|
| Longs | 2 | 50.0% | −2.9% | −2.9% | −13.7% | — | Too few quarters |
| Shorts | 27 | 63.0% | +3.6% | +6.6% | — | 0.60 | No reliable evidence |
| All positions | 29 | 62.1% | +3.1% | +6.6% | — | 0.56 | No reliable evidence |
Every quarter (30)
| From | Price paid | Return on equity the price implies | Return on equity delivered | Position | CGEN | S&P 500 |
|---|---|---|---|---|---|---|
| September 30, 2026 (open) | $2.38 | 15.5% | 44.8% | Long | −16.8% | −0.8% |
| June 30, 2026 | $2.14 | 14.2% | 44.8% | Long | +11.2% | +2.4% |
| March 31, 2026 | $2.13 | 14.2% | 44.8% | Long | +0.5% | +15.1% |
| September 30, 2025 | $1.47 | 16.9% | -23.6% | Short | +4.1% | +2.7% |
| June 30, 2025 | $1.78 | 19.9% | -23.6% | Short | −17.4% | +8.1% |
| March 31, 2025 | $1.46 | 16.8% | -23.6% | Short | +21.9% | +10.8% |
| September 30, 2024 | $1.81 | 17.0% | -26.2% | Short | −15.5% | +2.5% |
| June 30, 2024 | $1.68 | 16.0% | -26.2% | Short | +7.7% | +5.8% |
| March 31, 2024 | $2.58 | 23.2% | -26.2% | Short | −34.9% | +4.4% |
| September 30, 2023 | $0.93 | 8.7% | -36.5% | Short | +112.9% | +11.6% |
| June 30, 2023 | $1.14 | 10.1% | -36.5% | Short | −18.4% | −3.2% |
| March 31, 2023 | $0.70 | 7.2% | -36.5% | Short | +62.9% | +8.7% |
| September 30, 2022 | $0.66 | 5.6% | -30.2% | Short | +9.1% | +7.6% |
| June 30, 2022 | $1.85 | 11.3% | -30.2% | Short | −64.3% | −4.9% |
| March 31, 2022 | $3.22 | 17.8% | -30.2% | Short | −42.5% | −16.1% |
| September 30, 2019 | $4.23 | 40.2% | -67.9% | Short | +40.9% | +9.0% |
| June 30, 2019 | $3.84 | 36.7% | -67.9% | Short | +10.2% | +1.8% |
| March 31, 2019 | $4.14 | 39.4% | -67.9% | Short | −7.3% | +4.2% |
| September 30, 2017 | $3.80 | 20.8% | -41.1% | Short | −34.2% | +6.8% |
| June 30, 2017 | $3.80 | 20.8% | -41.1% | Short | 0.0% | +4.4% |
| March 31, 2017 | $4.30 | 23.2% | -41.1% | Short | −11.6% | +3.1% |
| September 30, 2016 | $6.30 | 23.7% | -20.6% | Short | −19.1% | +4.0% |
| June 30, 2016 | $6.48 | 24.3% | -20.6% | Short | −2.8% | +3.8% |
| March 31, 2016 | $5.58 | 21.3% | -20.6% | Short | +16.1% | +2.5% |
| September 30, 2015 | $5.17 | 16.6% | -16.1% | Short | +23.6% | +7.0% |
| June 30, 2015 | $6.94 | 21.5% | -16.1% | Short | −25.5% | −6.4% |
| March 31, 2015 | $7.05 | 21.8% | -16.1% | Short | −1.6% | +0.2% |
| September 30, 2014 | $8.57 | 65.2% | -56.8% | Short | −2.8% | +4.9% |
| June 30, 2014 | $8.99 | 68.3% | -56.8% | Short | −4.7% | +1.1% |
| March 31, 2014 | $10.51 | 79.4% | -56.8% | Short | −14.5% | +5.2% |
How the test works
At each quarter end since March 2010 we rebuild the models from Compugen LTD's quarters ending at least 90 days earlier (and no more than 200 days before that), using the figures as later filed, including any restatement, and value them at that day's close, adjusted for later share splits and spin-offs so that price and share count are on the same basis. A wide enough gap is a long or a short for one quarter (growth 10 points; margin and return on equity 5 points; a PEG under 0.75 or over 3), measured on total return against the S&P 500. The rules were set before the test. No trading or borrowing costs; today's list of companies. Not investment advice. All companies and the results across them.
Compare with peers
- Viridian Therapeutics, Inc.\de priced in
- Wave Life Sciences, Inc. priced in
- Assembly Biosciences, Inc. priced in
- Recursion Pharmaceuticals, Inc. priced in
- Cytokinetics Inc priced in
Head to head: CGEN vs VRDNCGEN vs WVEASMB vs CGEN
More: Biotechnology stocks compared, Health Care sector, rankings of US companies